8-phenyl-7-{4-[3-(5-pyridin-2-yl-1H-[1,2,4]triazol-3-yl)-azetidin-1-ylmethyl]-phenyl}-imidazo[1,2-c]pyrimidine | 1240108-33-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 8-phenyl-7-{4-[3-(5-pyridin-2-yl-1H-[1,2,4]triazol-3-yl)-azetidin-1-ylmethyl]-phenyl}-imidazo[1,2-c]pyrimidine
• 英文别名: 8-phenyl-7-[4-[[3-(3-pyridin-2-yl-1H-1,2,4-triazol-5-yl)azetidin-1-yl]methyl]phenyl]imidazo[1,2-c]pyrimidine
• CAS: 1240108-33-1
• 化学式: C₂₉H₂₄N₈
• 分子量: 484.563
• InChiKey: QPQOKNAHWGSRRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  87.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] FUSED PYRIMIDINES AS AKT INHIBITORS<br/>[FR] PYRIMIDINES CONDENSÉES EN TANT QU'INHIBITEURS D'AKT
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2010091824A1

  公开（公告）日：2010-08-19

  The present invention relates to compounds of formula (I), a N-oxide or tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6, R7, R10, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

  本发明涉及式(I)的化合物，其N-氧化物或互变异构体或立体异构体，或其盐，其中环B和与其融合的咪唑，R4、R6、R7、R10、m和n的含义如描述和权利要求中所给出，这些化合物是Pi3K/Akt途径的有效抑制剂，其生产过程及其作为药物的用途。
• FUSED PYRIMIDINES
  申请人：Beckers Barbara

  公开号：US20130310362A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of formula (I), a N-oxide or tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6, R7, R10, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

  本发明涉及式(I)化合物，其为N-氧化物或其互变异构体或立体异构体或其盐，其中环B和它融合的咪唑环，R4、R6、R7、R10、m和n的含义如说明书和权利要求中所给出的，它们是有效的Pi3K/Akt途径抑制剂，其生产过程以及它们作为药物的用途。
• FUSED PYRIMIDINES AS AKT INHIBITORS
  申请人：Bayer Intellectual Property GmbH

  公开号：EP2396331B1

  公开（公告）日：2013-10-16